These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 16925970)

  • 1. The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death.
    Nguyen DM; Yeow WS; Ziauddin MF; Baras A; Tsai W; Reddy RM; Chua A; Cole GW; Schrump DS
    Cancer J; 2006; 12(4):257-73. PubMed ID: 16925970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade.
    Reddy RM; Yeow WS; Chua A; Nguyen DM; Baras A; Ziauddin MF; Shamimi-Noori SM; Maxhimer JB; Schrump DS; Nguyen DM
    Apoptosis; 2007 Jan; 12(1):55-71. PubMed ID: 17136498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin.
    Tsai WS; Yeow WS; Chua A; Reddy RM; Nguyen DM; Schrump DS; Nguyen DM
    Mol Cancer Ther; 2006 Dec; 5(12):2977-90. PubMed ID: 17172403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.
    Yeow WS; Baras A; Chua A; Nguyen DM; Sehgal SS; Schrump DS; Nguyen DM
    J Thorac Cardiovasc Surg; 2006 Dec; 132(6):1356-62. PubMed ID: 17140955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway.
    Shamimi-Noori S; Yeow WS; Ziauddin MF; Xin H; Tran TL; Xie J; Loehfelm A; Patel P; Yang J; Schrump DS; Fang BL; Nguyen DM
    Cancer Gene Ther; 2008 Jun; 15(6):356-70. PubMed ID: 18309355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
    Stewart JH; Tran TL; Levi N; Tsai WS; Schrump DS; Nguyen DM
    J Surg Res; 2007 Jul; 141(1):120-31. PubMed ID: 17574045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation.
    Ziauddin MF; Yeow WS; Maxhimer JB; Baras A; Chua A; Reddy RM; Tsai W; Cole GW; Schrump DS; Nguyen DM
    Neoplasia; 2006 Jun; 8(6):446-57. PubMed ID: 16820090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP; Zisman A; Bonavida B
    Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
    Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
    Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.
    Frese S; Brunner T; Gugger M; Uduehi A; Schmid RA
    J Thorac Cardiovasc Surg; 2002 Jan; 123(1):168-74. PubMed ID: 11782771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
    Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
    Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
    Ng CP; Bonavida B
    Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
    Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
    Pollack IF; Erff M; Ashkenazi A
    Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo.
    Shankar S; Chen X; Srivastava RK
    Prostate; 2005 Feb; 62(2):165-86. PubMed ID: 15389801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines.
    Siervo-Sassi RR; Marrangoni AM; Feng X; Naoumova N; Winans M; Edwards RP; Lokshin A
    Cancer Lett; 2003 Feb; 190(1):61-72. PubMed ID: 12536078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells.
    Wu XX; Kakehi Y; Mizutani Y; Nishiyama H; Kamoto T; Megumi Y; Ito N; Ogawa O
    Int J Cancer; 2003 Apr; 104(4):409-17. PubMed ID: 12584736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S; Almasan A
    Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
    J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Ad-sTRAIL with the chemotherapeutic drug cisplatin synergistically enhances their pro-apoptotic ability in human breast cancer cells.
    Liu X; Wang J; Wang H; Liu S; Liang Y; Lv Z; Zhou Q; Ding W
    Oncol Rep; 2013 Oct; 30(4):1913-9. PubMed ID: 23912708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.